Vikram Paradkar News Today

As of now, Gennova Biopharmaceuticals has launched a vaccine, Gemcovac-OM, which is based on the Omicron variant.

According to respective company sources, 200 million doses of Corbevax while 50 million doses of Covaxin are ready to dispatch as and when orders are received

The vaccine is found safe & immunogenic in 5-18 age group

In June, the Drugs Controller General of India had approved Corbevax as the first mix-and-match booster dose in the country.

Experts say India’s Covid-19 vaccine policy needs an overhaul to keep up with new data and new variants of coronavirus. 

India has long been called the world’s pharmacy as the largest producer of generic drugs as well as vaccines on the globe. A lot of that capacity was repurposed and increased to produce COVID vaccines, intended particularly for low-income countries. But demand has dwindled, creating a glut even as vast regions remain largely unvaccinated. Fred de Sam Lazaro reports from India.

Biological E said its multiple manufacturing units in Hyderabad are fully qualified to enable production of around 1 billion dosages of Corbevax annually.

As on date, the company has produced 30 crore vaccines as part of its commitment made to the Government of India, with 5 crore dosages already supplied